Klas Bergenheim
Director Health Economics & Payer Evidence V&I, AstraZeneca
Klas Bergenheim is listed as Director Health Economics & Payer Evidence V&I, AstraZeneca. Klas spoke at ISPOR Europe 2026 in November 2026 (speaker, “Converting Vaccine Evidence to Policy”). Speaks mainly at Government Administration events.
Compiled from published conference agendas; not yet confirmed by Klas. Is this you? Claim this profile.
- Sector: Government Administration
Sessions at 1 conference
ISPOR Europe 2026 8 November 2026 – 11 November 2026
- Converting Vaccine Evidence to Policy Speaker · 9 November 2026
Spoke alongside
People who have shared a session with Klas at events on B2DB.
- Cheryl Jones Maverex Limited 1 shared session
- Isidoros Kougioumtzoglou University of West Attica 1 shared session
- Patricia Pujol Medical Affairs Manager · GSK 1 shared session
- Tiberius Certejan Senior Director, Market Access and Government Affairs, Region Europe · Merz Therapeutics GmbH 1 shared session
Others from AstraZeneca
- Paul Hudson President, AstraZeneca US and Executive Vice President, North America 5 sessions
- Jarosław Oleszczuk Speaker 4 sessions
- Shaun Grady Chair of AstraZeneca UK 4 sessions
- Gabriel Wong Senior Director Physician, Clinical Research, Immunology 3 sessions
- Olga Obrezanova Principal Scientist, Augmented Biologics Design 3 sessions
- Agnieszka Jozwik Senior Research Scientist, Functional Genomics 2 sessions
- Christof Jaeger Senior Director - Data Science & Modelling - Substance, Pharmaceutical Sciences 2 sessions
- Goran Dahl Associate Principal Scientist 2 sessions
- James Fleming Scientist 2 sessions
- Jarrod Walsh Director of Biochemical & Biophysical Screening 2 sessions
- Melanie Leveridge Vice President Assays, Profiling & Cell Sciences 2 sessions
- Miranda Cooper Statistical Science Director 2 sessions